Saturday, October 31, 2026

AI-native vendors capture 45% of enterprise deals as legacy software loses ground globally

AI-native vendors secured 40-45% of new enterprise platform deals in H2 2025, up from 25% a year earlier, as companies worldwide abandon legacy systems struggling with AI integration. Chinese tech giant Baidu's AI cloud reached $4.1 billion in revenue while SoundHound AI reported record Q4 deals. Enterprises now specify 'native AI architecture' in procurement, effectively disqualifying retrofitted solutions.

AI-native vendors capture 45% of enterprise deals as legacy software loses ground globally
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

AI-native vendors captured 40-45% of new enterprise platform deals in H2 2025, nearly doubling their 25% share from a year earlier, as companies worldwide shift from legacy software unable to integrate AI effectively.

SoundHound AI CEO Keyvan Mohajer reported record customer deals in Q4 2025 across all profit metrics. "Businesses are partnering with AI natives as traditional software faces massive disruption," Mohajer said. In China, Baidu's AI cloud business reached CNY 30 billion ($4.1 billion) in revenue, demonstrating global enterprise demand for integrated platforms.

The shift stems from enterprises avoiding technical debt. Legacy systems require expensive middleware to connect AI features, creating performance bottlenecks and security gaps. AI-native platforms eliminate these layers by designing data pipelines, model serving, and applications as unified systems.

Rezolve AI noted most legacy digital experience platforms lack native AI, conversational interfaces, or transaction-capable agents. Enterprises now prioritize vendors combining proprietary LLMs with deep platform integration—capabilities traditional providers struggle to retrofit.

Traditional vendors face a dilemma: rushing AI features risks quality, but slow rollouts lose customers to AI-first competitors. Many enterprises now specify "native AI architecture" in RFPs, disqualifying retrofitted solutions. The procurement shift spans financial services, healthcare, and manufacturing globally.

Three factors drive adoption. First, AI-native vendors optimize hardware and software together, improving inference speed and cost efficiency. Second, their development cycles outpace enterprise IT departments upgrading legacy stacks. Third, integrated architecture eliminates middleware complexity.

Contract economics reflect the divide. AI-native platforms command premium pricing while legacy vendors discount to retain accounts. Buyers increasingly favor vendors who built AI capabilities from inception rather than acquisition.

If trends continue, traditional software companies may require acquisitions or complete platform rebuilds to compete in AI-dependent workflows. The 20-point market share gain in one year suggests enterprise AI procurement has reached an inflection point favoring purpose-built systems over adapted legacy infrastructure.


Sources:
1 Yahoo Finance, "SoundHound Grew Revenue 59% but Its Stock Is Down 30% This Year" (March 21, 2026)
2 Nasdaq, "Why SoundHound AI Stock Took it on the Chin Today" (March 19, 2026)
3 Globe Newswire, "Willis partners with Circle Asia to launch Asia’s first insurance facility for collectors and galler" (March 23, 2026)
4 Yahoo Finance, "CNOOC Names Huang Yongzhang as Chief Executive Officer" (March 23, 2026)
5 Yahoo Finance, "Tencent’s ClawBot Links WeChat And OpenClaw In AI Agent Push" (March 22, 2026)

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com